医学
肺结核
药品
丙型肝炎病毒
病毒学
丙型肝炎
肝病
疾病
免疫学
病毒
药理学
内科学
病理
作者
Seung Won,Jiao Wang,You-fu Zhu
出处
期刊:PubMed
日期:2022-01-20
卷期号:30 (1): 113-116
标识
DOI:10.3760/cma.j.cn501113-20201224-00675
摘要
Clinically, patients with tuberculosis (TB) combined with hepatitis C virus (HCV) infection often require simultaneous treatment. Consequently, when anti-HCV and TB drugs are used in combination drug-drug interactions (DDIs), anti-TB drug-induced hepatotoxicity, and liver disease states need to be considered. This paper focuses on discussing the metabolic mechanisms of commonly used anti-TB and HCV drugs and the selection options of combined drugs, so as to provide rational drug use for TB patients combined with HCV infection.临床上经常遇到结核病(TB)合并丙型肝炎病毒(HCV)感染者需要同时治疗。当抗HCV和抗TB药物联用时需要考虑药物-药物之间的相互作用(DDIs)、抗TB药物诱导的肝毒性,以及肝脏疾病状态。现重点讨论常用抗TB和抗HCV药物的代谢机制和联用药物的选择,为TB合并HCV感染患者提供合理的用药选择。.
科研通智能强力驱动
Strongly Powered by AbleSci AI